Concerns about the latest NICE draft guidance on statinsBMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g4130 (Published 09 July 2014) Cite this as: BMJ 2014;349:g4130
- Klim McPherson, visiting professor of public health epidemiology1
- 1New College, Oxford, UK
Recommending that five million more people take statins lifelong for primary prevention of cardiovascular disease without knowing enough about the side effects is foolhardy.1 The data on side effects need to be public and scrutinised by qualified independent assessors.
My epidemiological experience of commercial bias comes from studying the safety of third generation oral contraceptives and hormone replacement therapy (HRT). In both cases there was strong evidence for bias in published …
Log in using your username and password
Log in through your institution
Sign up for a free trial